Business Context and Reporting Period
Company: Laboratory Corporation of America Holdings (LabCorp)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2004
Business Overview: The Company operates in a single segment providing clinical laboratory testing services. Operations were negatively impacted by severe weather in the Southeastern U.S. during the quarter. The Company completed the acquisition of DIANON Systems, Inc. in January 2003, which is fully integrated into current results.
Key Financial Metrics
| Metric ($ Millions) | 3 Months Ended Sept 30, 2004 | 9 Months Ended Sept 30, 2004 | 3 Months Ended Sept 30, 2003 | 9 Months Ended Sept 30, 2003 |
|---|---|---|---|---|
| Net Sales | $781.5 | $2,318.3 | $752.0 | $2,207.9 |
| Gross Profit | $325.9 | $983.2 | $310.9 | $923.9 |
| Operating Income | $152.8 | $461.3 | $135.4 | $403.0 |
| Net Earnings | $92.6 | $278.2 | $83.1 | $243.4 |
| Diluted EPS | $0.66 | $1.97 | $0.58 | $1.67 |
| Cash from Operations (9mo) | $431.5 | $420.1 | ||
| Cash & Equivalents (Sept 30, 2004) | $213.7 | $30.0 (Sept 30, 2003) | ||
| Total Debt (Long-term + Current) | ~$886.8 | ~$879.8 |
Note: Total Debt includes Zero coupon-subordinated notes ($531.0M), 5 1/2% senior notes ($353.5M), and other long-term debt ($2.0M + $0.3M current).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 3.9% ($29.5M) for the quarter and 5.0% ($110.4M) for the nine months. Growth was driven by a 1.8% volume increase in the quarter (10% growth in genomic/esoteric testing) and a 2.1% price increase. Nine-month volume growth was 4.2% with a 1% price increase.
- Profitability: Operating income rose 12.9% for the quarter and 14.5% for the nine months. Gross margin improved slightly to 41.7% (quarter) and 42.4% (nine months) due to cost reduction programs and synergies from prior acquisitions.
- Expenses: Selling, general, and administrative (SG&A) expenses decreased as a percentage of sales (20.8% vs 21.6% in the quarter) due to improved billing/collection performance and reduced bad debt expense. Interest expense declined due to debt reductions following the 2003 DIANON acquisition financing.
- Weather Impact: Management estimates severe weather negatively impacted revenue by approximately $7.5M (1%) in the quarter and 0.3% for the nine months.
Guidance, Outlook, and Risks
- Capital Allocation: The Company completed a $250.0M stock repurchase program in the first nine months of 2004. On October 20, 2004, the Board authorized a new $250.0M repurchase program effective in the fourth quarter.
- Capital Expenditures: CapEx for the nine months was $59.1M. Total 2004 CapEx is expected to be approximately $90.0M, funded by operating cash flow, to improve information systems and automate laboratory processes.
- Liquidity: The Company maintains $150.0M and $200.0M revolving credit facilities with no outstanding balances as of September 30, 2004. Management believes liquidity is sufficient for short and long-term needs.
- Accounting Changes: The Company will adopt EITF Issue No. 04-8 regarding contingently convertible debt, which will retroactively reduce diluted EPS for prior periods presented (estimated reduction of $0.03 to $0.10 per share depending on the period).
- Risks and Contingencies:
- Legal: The Company is defending against consolidated shareholder class actions alleging securities fraud (2002 period) and patent infringement suits (Chiron Inc. regarding Hepatitis C and HIV testing). A patent judgment of $7.8M was affirmed on appeal and paid.
- Regulatory: Risks include changes in reimbursement policies, HIPAA compliance, and potential sanctions from government investigations.
- Debt: Zero coupon-subordinated notes ($531.0M) contain embedded derivatives and may be put to the Company in 2006 or 2011.
Investor Verification Checklist
- Stock Repurchase Execution: Verify the commencement and volume of the new $250M buyback program authorized in October 2004.
- Legal Exposure: Monitor the status of the consolidated securities fraud class action and the Chiron patent litigation for potential material financial impact.
- Debt Maturity: Review the terms of the zero coupon-subordinated notes regarding the 2006 put option and the Company's liquidity position to meet that obligation.
- EPS Impact: Confirm the retroactive restatement of diluted EPS figures in future filings due to the adoption of EITF 04-8.
- Reimbursement Rates: Track changes in federal and third-party payor reimbursement rates, which are a primary risk factor for the clinical laboratory industry.